I-Mab Announces Upcoming Participation at June Conferences

Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced its participation in several upcoming healthcare conferences in June 2021. Key events include the Jefferies Healthcare Conference on June 1 and various one-on-one meetings from June 2-4 and June 7-10. Notably, Dr. Joan Huaqiong Shen will present at the Haitong Annual Investor Conference on June 16. The company aims to advance its mission of developing innovative biologics in immuno-oncology, boasting a robust pipeline of over 15 clinical and pre-clinical candidates.

Positive

• Participation in multiple healthcare conferences could enhance visibility and attract investors.
• The company has a competitive pipeline with over 15 drug candidates, indicating strong R&D capabilities.

Negative

• None.

SHANGHAI and GAITHERSBURG, Md., May 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in June. Details of the conferences and management presentation are as follows:

Jefferies Healthcare Conference (Virtual)
Fireside chat: Tuesday, June 1, 2021 at 3:00 p.m.ET
Speaker: Dr. Jingwu Zang, Founder, Chairman and Director

Webcast link: https://wsw.com/webcast/jeff174/imab/1821663. The webcast will also be available under "Event Calendar" on IMAB's IR website at http://ir.i-mabbiopharma.com/.

One-on-one meetings: June 2-4, 2021
Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Mr. Tianyi Zhang, Executive Director Investor Relations

For more information, please contact your Jefferies representative.

Huatai Securities 2021 Interim Investment Strategy Conference
Management participant: Mr. Tianyi Zhang, Executive Director Investor Relations

One-on-one and small group meetings: June 2-3, 2021
Location: InterContinental Global Center, Chengdu

For more information, please contact your Huatai representative.

Credit Suisse Asia Healthcare Corporate Day (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Mr. Tianyi Zhang, Executive Director Investor Relations

One-on-one and small group meetings: June 7-10, 2021

For more information, please contact your Credit Suisse representative.

BofA 2021 Innovative China Conference (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, Mr. Tianyi Zhang, Executive Director Investor Relations

One-on-one and small group meetings: June 11, 2021

For more information, please contact your BofA representative.

Haitong Annual Investor Conference – Innovative Medicine CEO Forum
Keynote Presentation: Wednesday, June 16, 2021 at 10:00 a.m. China Time
Presenter: Dr. Joan Huaqiong Shen, Director and Chief Executive Officer
Location: Shangri-La Hotel, Shanghai

Small group meetings: June 16, 2021
Management participant: Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Tianyi Zhang, Executive Director Investor Relations

For more information, please contact your Haitong representative.

Goldman Sachs Hybrid Healthcare Corporate Day (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, Mr. Tianyi Zhang, Executive Director Investor Relations

One-on-one and small group meetings: June 22-24, 2021

For more information, please contact your Goldman Sachs representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

For more information, please contact:

I-Mab

Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5785

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: +86 21 6039 8363

View original content:http://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-june-conferences-301300595.html

SOURCE I-Mab

FAQ

What conferences will I-Mab participate in June 2021?

I-Mab will participate in the Jefferies Healthcare Conference, Huatai Securities 2021 Interim Investment Strategy Conference, Credit Suisse Asia Healthcare Corporate Day, BofA 2021 Innovative China Conference, Haitong Annual Investor Conference, and Goldman Sachs Hybrid Healthcare Corporate Day.

Who are the key speakers for I-Mab at the June conferences?

Key speakers include Dr. Jingwu Zang, Dr. Joan Huaqiong Shen, Mr. Jielun Zhu, and Mr. Tianyi Zhang.

What is the focus area of I-Mab's pipeline?

I-Mab focuses on the discovery and development of novel biologics, specifically in the immuno-oncology therapeutic area.

How many drug candidates does I-Mab currently have?

I-Mab has a pipeline of more than 15 clinical and pre-clinical stage drug candidates.

What is I-Mab's mission?

I-Mab aims to bring transformational medicines to patients worldwide through innovative drug development.